Altimmune reports Q3 2026 results as pemvidutide programs advance in MASH and AUD
The company said its PERFORMA Phase 3 MASH trial is progressing as planned and an FDA End-of-Phase 2 meeting for alcohol use disorder is set for December 2026.
SEC filing (2)